Canada: Pharma In Brief - Data Protected: "Innovative Drug" Status Prevents Generic NOC

Case: (1) Hospira Healthcare Corp v Canada (Health) and Sanofi-Aventis, 2015 FC 1205
Case: (2) Hospira Healthcare Corp v Canada (Health) and Sanofi-Aventis, 2015 FC 1206

Drug: ELOXATIN® (oxaliplatin)

Nature of case: (1) Judicial review of Minister's decision to not issue an NOC based on "innovative drug" data protection
Nature of case: (2) Judicial review of Minister's decision to not issue an NOC based on an incomplete SNDS

Successful party: Health Canada and Sanofi-Aventis

Date of decision: November 6, 2015

Summary

Sanofi-Aventis (Sanofi) markets and sells oxaliplatin, used for the treatment of life-threatening colorectal cancer, in Canada under the brand name ELOXATIN® for use in the treatment of colorectal cancer. Hospira Healthcare Corp (Hospira) brought two applications for judicial review of two ministerial decisions regarding the approval of two of its generic oxaliplatin products for the same treatment indication.

In 2015 FC 1205 (the First Application), the Federal Court held that where a second-entry manufacturer amends its drug submission post-filing to make a comparison to the brand-name product, the Minister cannot issue a Notice of Compliance (NOC) until data protection for the brand-name product had expired.

In 2015 FC 1206 (the Second Application), the Federal Court held that it did not need to decide if the PM(NOC) Regulations were engaged since the patent that had been listed on the patent register in respect of ELOXATIN® had expired by the date of the hearing.

Sanofi's ELOXATIN® benefitted from data protection

On November 20, 2006, Sanofi filed an NDS for approval to market and sell ELOXATIN®, used for the treatment of life-threatening colorectal cancer, in Canada and was granted priority review status. The Minister issued an NOC for ELOXATIN® (in both a dried powder form and a solution form for injection) on June 15, 2007 and granted data protection until December 15, 2015.

Hospira's NDS and post-filing amendment

Hospira filed an NDS for oxaliplatin (dried powder injection product) on October 27, 2006 supported by literature references and post-market experiences.  The Hospira NDS was rejected initially at the screening stage  on the basis that no clinical or pre-clinical data had been supplied, but was ultimately refiled with the Minister for redetermination pursuant to a decision of the Federal Court of Appeal in which the Court also stressed that the Minister had discretion to determine the nature and form of the information necessary to meet the requirements of safety and efficacy.

Hospira's NDS was accepted for examination on June 3, 2011 and on March 28, 2012, the Minister issued a Notice of Non-Compliance (NON) for Hospira's proposed product.

On July 24, 2012, Hospira made a post-filing amendment to its NDS to reference the Summary Basis of Decision and Product Monograph for ELOXATIN®.  On October 31, 2013, the Minister refused to issue Hospira an NOC until the data protection on ELOXATIN® had expired.

Data protection applies to post-filing amendments

Hospira argued that, since the reference to ELOXATIN® was made in post-filing amendments to an NDS, it is not subject to a data protection prohibition. The relevant provision of the Food and Drug Regulations is C.08.004.1(3). Justice Gagné rejected this argument and held, when read as a whole, it is "clear that post-filing amendments are subject to the data protection prohibition imposed on the Minister". Justice Gagné dismissed the First Application and upheld the Minister's determination that an NOC for Hospira's oxaliplatin could not be issued until the data protection on ELOXATIN® had expired (December 15, 2015).

No lack of procedural fairness

Hospira argued that it should have been informed earlier that data protection would prevent issuance of its NOC and, since it was not, that it had been denied procedural fairness. Justice Gagné rejected this argument and held that there was no lack of procedural fairness for two reasons: (i) the Minister must first determine that a drug is safe and effective before deciding issues related to data protection; and (ii) Hospira could have, but did not, avail itself of the reconsideration process in response to the Minister's decision of October 31, 2013.

Second application is moot

The Minister rejected Hospira's SNDS (solution injection product) on the basis that it did not include a Form V in respect of the patent listed in respect of ELOXATIN® (solution form for injection), which Hospira argued was in error.

Justice Gagné held that the issue was moot for two reasons.  First, the patent listed in respect of ELOXATIN® had expired and a prohibition order could no longer be granted pursuant to the PM(NOC) Regulations.  Second, Sanofi's ELOXATIN® (both the dried powder and the solution injection products) benefitted from data protection until December 15, 2015.  Even if the Court had found in the First Application that ELOXATIN®'s data protection did not prevent the issuance of an NOC for Hospira's dried powder injectable product, Hospira's SNDS was filed after Sanofi had received its NOC and data protection would apply.

Link to decisions:

Hospira Healthcare Corporation v. Canada (Health), 2015 FC 1205

Hospira Healthcare Corporation v. Canada (Health), 2015 FC 1206

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions